On 24 June, Vaccentis held a cross-functional Advisory Board under the leadership of our Head of R&D and CMO Ingrid Rauter.
Participants from urology, oncology, pharmacology, pathology, and rheumatology were represented. The future direction of our Phase 2b clinical trial was discussed and aligned.
